Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
| IN VIVO: The Business and Medicine Report |
|
IN VIVO is
the premier strategic business resource for the biopharma, medtech, and
diagnostics industries.
IN VIVO delivers:
- Revealing, in-depth coverage of your
competitors' strategies
- Incisive projections of future industry
trends and their implications for your business
- Expert analysis of key industry developments
- Exclusive interviews with top industry
executives and analysts
- In-depth examination of dealmaking,
marketing, R&D, regulatory, and finance strategies --
those that were successful and those that missed the mark
Includes FREE subscription to Health
News Daily
|
|
|
|
| START-UP: Emerging Medical Ventures |
 |
START-UP: No publication reviews
leading edge companies and technology better than START-UP.
Each issue of START-UP profiles the most important new
product companies, identifies the hottest technology areas,
reviews funds flowing into private companies and investment
trends, and reports on university tech transfer licensing. Industries
covered: pharmaceuticals, biotechnology, medical
equipment & devices, and in vitro diagnostics.
Includes FREE subscription to Health
News Daily
|
|
|
|
| The
RPM Report: Regulation • Policy •
Market Access |
 |
To help you make sense of the complicated
and often arcane regulatory world, we have launched a new monthly publication, The RPM Report:
Regulation, Policy and Market Access.
From the RPM Report, you'll get easy-to-understand,
practical insight on the regulatory and policy issues you need
to know. You'll learn the "so what" behind the latest
from the FDA and CMS that you readily can apply to the success
of your business. Learn more at therpmreport.com.
Includes FREE subscription to Health
News Daily
|
|
|
|
| Medtech Insight Newsletter |
|
Medtech Insight delivers the quality
content you need on medical technologies impacting the spectrum
of surgical, orthopedic, cardiovascular, and other markets.
Written and edited by seasoned industry participants and experts,
the Medtech Insight newsletter provides insights into
the technology and market developments (devices, instrumentation,
biomaterials, gene therapy, tissue engineering, etc.) impacting
a wide range of surgical and non-surgical clinical practices
(cardiothoracic & vascular surgery, general surgery, orthopedics
& spine surgery, interventional radiology/cardiology, etc.).
Learn more at www.medtechinsight.com.
Includes FREE subscription to Health
News Daily
|
|
|
|
|
Medtech Insight Reports
are comprehensive analyses of the devices, technologies, procedures, and companies shaping the global medical technology market. We are the leading and most trusted provider of off-the-shelf medical technology market reports. To find out about upcoming reports, custom reports, or corporate intelligence subscriptions, contact reports@elsevier.com or call +1-949-453-0071. Learn more at www.medtechinsight.com. |
|
|
Medical Devices Today
provides complimentary news articles, industry announcements and analysis of key
developments in the medical device and diagnostics industries. Medical Devices
Today was created to give readers access to some of the unique content from
Elsevier Business Intelligence publications, including:
- "The Gray Sheet"
- Medtech Insight
- "The Silver Sheet"
|
- IN VIVO
- Start-Up
- Strategic Transactions
|
|
In addition to visiting the website, readers can sign up to receive a
free weekly email
update. |
|
|
|
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
